NSABP B-43: A Phase III Clinical Trial Comparing Trastumumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy

Objective

This is a clinical trial of Trastuzumab added to breast radiation therapy. Trastuzumab is an investigational treatment.

IRB Protocol Number

08-1266

Principal Investigator(s)

NICOLE KOUNALAKIS

Cancer Trials

• Breast Cancer

Sponsor(s)

NSABP

Contact

ANNA HARVEY at 720-848-0689
or ANNA.HARVEY@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period that can last up to 3-6 weeks. A follow up period will consist of clinic visits. // Eligibility criteria : includes but is not limited to 18 years or older